Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults

Tim R. Cressey*, Rohan Hazra, Andrew Wiznia, Marc Foca, Patrick Jean-Philippe, Bobbie Graham, Jennifer R. King, Paula Britto, Vincent J. Carey, Edward P. Acosta, Ram Yogev

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

Original languageEnglish (US)
Pages (from-to)1333-1335
Number of pages3
JournalPediatric Infectious Disease Journal
Volume35
Issue number12
DOIs
StatePublished - Nov 28 2016

Keywords

  • Antiretrovirals
  • Atazanavir
  • Pediatrics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults'. Together they form a unique fingerprint.

Cite this